JP2017503823A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503823A5 JP2017503823A5 JP2016547847A JP2016547847A JP2017503823A5 JP 2017503823 A5 JP2017503823 A5 JP 2017503823A5 JP 2016547847 A JP2016547847 A JP 2016547847A JP 2016547847 A JP2016547847 A JP 2016547847A JP 2017503823 A5 JP2017503823 A5 JP 2017503823A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- pridopidine
- oral dosage
- solid oral
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007787 solid Substances 0.000 claims description 245
- 239000006186 oral dosage form Substances 0.000 claims description 243
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 claims description 228
- 229950003764 pridopidine Drugs 0.000 claims description 228
- 150000003839 salts Chemical class 0.000 claims description 96
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 72
- 238000013270 controlled release Methods 0.000 claims description 43
- 239000002552 dosage form Substances 0.000 claims description 35
- 238000001727 in vivo Methods 0.000 claims description 30
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 19
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 19
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 19
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 19
- 230000000642 iatrogenic effect Effects 0.000 claims description 16
- 239000000314 lubricant Substances 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 14
- 239000000945 filler Substances 0.000 claims description 12
- 239000008363 phosphate buffer Substances 0.000 claims description 11
- 239000001856 Ethyl cellulose Substances 0.000 claims description 10
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 10
- 229920001249 ethyl cellulose Polymers 0.000 claims description 10
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 9
- 239000004359 castor oil Substances 0.000 claims description 9
- 235000019438 castor oil Nutrition 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 9
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 8
- 208000023105 Huntington disease Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 8
- 229920000642 polymer Polymers 0.000 claims description 8
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 8
- 201000000980 schizophrenia Diseases 0.000 claims description 8
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000004014 plasticizer Substances 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 4
- 208000020925 Bipolar disease Diseases 0.000 claims description 4
- 208000012661 Dyskinesia Diseases 0.000 claims description 4
- 208000014094 Dystonic disease Diseases 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 208000004547 Hallucinations Diseases 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 4
- 206010034010 Parkinsonism Diseases 0.000 claims description 4
- 208000028017 Psychotic disease Diseases 0.000 claims description 4
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 claims description 4
- 208000029560 autism spectrum disease Diseases 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 208000028683 bipolar I disease Diseases 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims description 4
- 208000010118 dystonia Diseases 0.000 claims description 4
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 4
- 230000036651 mood Effects 0.000 claims description 4
- 230000003232 mucoadhesive effect Effects 0.000 claims description 4
- 208000019116 sleep disease Diseases 0.000 claims description 4
- 239000000454 talc Substances 0.000 claims description 4
- 229910052623 talc Inorganic materials 0.000 claims description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 4
- 208000028698 Cognitive impairment Diseases 0.000 claims description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000008203 oral pharmaceutical composition Substances 0.000 claims description 3
- 208000020685 sleep-wake disease Diseases 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- 235000011132 calcium sulphate Nutrition 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 229940049654 glyceryl behenate Drugs 0.000 claims description 2
- 239000001087 glyceryl triacetate Substances 0.000 claims description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920000193 polymethacrylate Polymers 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- -1 retalac® Substances 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 208000011117 substance-related disease Diseases 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 229960002622 triacetin Drugs 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 239000001069 triethyl citrate Substances 0.000 claims description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 2
- 235000013769 triethyl citrate Nutrition 0.000 claims description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 239000004081 narcotic agent Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 241000208822 Lactuca Species 0.000 description 3
- 235000003228 Lactuca sativa Nutrition 0.000 description 3
- 239000008183 oral pharmaceutical preparation Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 208000007848 Alcoholism Diseases 0.000 description 2
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 2
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 2
- 208000018526 Narcotic-Related disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 201000005040 opiate dependence Diseases 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461930358P | 2014-01-22 | 2014-01-22 | |
| US61/930,358 | 2014-01-22 | ||
| US201462050626P | 2014-09-15 | 2014-09-15 | |
| US62/050,626 | 2014-09-15 | ||
| PCT/US2015/012248 WO2015112601A1 (en) | 2014-01-22 | 2015-01-21 | Modified release formulations of pridopidine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019179329A Division JP7266298B2 (ja) | 2014-01-22 | 2019-09-30 | プリドピジンの調節放出製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017503823A JP2017503823A (ja) | 2017-02-02 |
| JP2017503823A5 true JP2017503823A5 (https=) | 2018-03-01 |
| JP6949487B2 JP6949487B2 (ja) | 2021-10-13 |
Family
ID=53543863
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016547847A Active JP6949487B2 (ja) | 2014-01-22 | 2015-01-21 | プリドピジンの調節放出製剤 |
| JP2019179329A Active JP7266298B2 (ja) | 2014-01-22 | 2019-09-30 | プリドピジンの調節放出製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019179329A Active JP7266298B2 (ja) | 2014-01-22 | 2019-09-30 | プリドピジンの調節放出製剤 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20150202302A1 (https=) |
| EP (2) | EP4049657A1 (https=) |
| JP (2) | JP6949487B2 (https=) |
| KR (1) | KR102479759B1 (https=) |
| CN (1) | CN106170287A (https=) |
| AU (1) | AU2015209411A1 (https=) |
| CA (1) | CA2937243C (https=) |
| CL (1) | CL2016001874A1 (https=) |
| DK (1) | DK3096759T3 (https=) |
| EA (1) | EA201691454A1 (https=) |
| ES (1) | ES2911800T3 (https=) |
| HU (1) | HUE058288T2 (https=) |
| IL (2) | IL246598B (https=) |
| MX (1) | MX377576B (https=) |
| PE (1) | PE20161220A1 (https=) |
| PL (1) | PL3096759T3 (https=) |
| TW (1) | TW201605446A (https=) |
| UA (1) | UA122053C2 (https=) |
| UY (1) | UY35962A (https=) |
| WO (1) | WO2015112601A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| JP2013536825A (ja) | 2010-09-03 | 2013-09-26 | イバックス・インターナショナル・ゲーエムベーハー | ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体 |
| TWI579272B (zh) | 2011-12-08 | 2017-04-21 | 梯瓦製藥國際有限責任公司 | 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽 |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| HK1221646A1 (zh) | 2013-06-21 | 2017-06-09 | Teva Pharmaceuticals International Gmbh | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 |
| MX377576B (es) | 2014-01-22 | 2025-03-04 | Prilenia Neurotherapeutics Ltd | Formulaciones de pridopidina de liberación modificada. |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| MX2017008136A (es) | 2014-12-22 | 2018-03-06 | Teva Pharmaceuticals Int Gmbh | Sal de l-tartrato de pridopidina. |
| JP6887952B2 (ja) | 2015-02-25 | 2021-06-16 | プリレニア ニューロセラピューティクス リミテッド | 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用 |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| EP3324967A4 (en) * | 2015-07-22 | 2019-03-20 | Prilenia Therapeutics Development Ltd. | PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| JP7034488B2 (ja) * | 2016-02-24 | 2022-03-14 | プリレニア・ニューロセラピューティクス・エルティーディー | プリドピジンを使用する神経変性眼疾患の治療 |
| EP4516356A3 (en) | 2016-08-24 | 2025-05-14 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating functional decline |
| CA3035099C (en) * | 2016-08-24 | 2023-01-17 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating dystonias |
| HUE058314T2 (hu) * | 2016-09-16 | 2022-07-28 | Prilenia Neurotherapeutics Ltd | Pridopidin alkalmazása Rett-szindróma kezelésére |
| US12102627B2 (en) * | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| CA3050700C (en) | 2017-01-20 | 2023-10-03 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for the treatment of fragile x syndrome |
| SI4154882T1 (sl) | 2017-08-14 | 2026-01-30 | Prilenia Neurotherapeutics Ltd. | Zdravljenje amiotrofične lateralne skleroze s pridopidinom |
| CA3073568A1 (en) * | 2017-08-30 | 2019-03-07 | Prilenia Neurotherapeutics Ltd. | High concentration dosage forms of pridopidine |
| JP2020533296A (ja) | 2017-09-08 | 2020-11-19 | プリレニア ニューロセラピューティクス リミテッド | 薬物誘発性ジスキネジアを治療するためのプリドピジン |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| KR20200056071A (ko) | 2018-11-14 | 2020-05-22 | 한화토탈 주식회사 | 내열성, 강성 및 용융 강도가 우수한 폴리올레핀 수지 조성물 |
| CN113395964A (zh) * | 2019-02-04 | 2021-09-14 | 普瑞尼亚神经治疗有限公司 | 用于帕金森氏病和与帕金森症相关的其它疾病的低剂量普利多匹定 |
| CN116472043A (zh) * | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
| WO2024258929A1 (en) * | 2023-06-12 | 2024-12-19 | Unravel Biosciences, Inc. | Methods for treating diseases associated with taf1 loss of function |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4020983B2 (ja) * | 1995-07-07 | 2007-12-12 | 帝國製薬株式会社 | 持続性製剤およびその製法 |
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| CA2403380A1 (en) * | 2000-03-21 | 2002-09-19 | Nippon Shinyaku Co., Ltd. | Sustained release oral preparations |
| AR030557A1 (es) * | 2000-04-14 | 2003-08-27 | Jagotec Ag | Una tableta en multicapa de liberacion controlada y metodo de tratamiento |
| GB0125088D0 (en) * | 2001-10-18 | 2001-12-12 | Smithkline Beecham Cork Ltd | New use |
| MXPA06002455A (es) * | 2003-09-02 | 2006-08-31 | Pfizer Prod Inc | Formas de dosificacion de liberacion sostenida de ziprasidona. |
| CA2584831C (en) | 2004-10-13 | 2013-09-17 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
| US20110206782A1 (en) * | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| TWI579272B (zh) * | 2011-12-08 | 2017-04-21 | 梯瓦製藥國際有限責任公司 | 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽 |
| AU2013243461A1 (en) | 2012-04-04 | 2014-11-06 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for combination therapy |
| HK1221646A1 (zh) * | 2013-06-21 | 2017-06-09 | Teva Pharmaceuticals International Gmbh | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 |
| MX377576B (es) | 2014-01-22 | 2025-03-04 | Prilenia Neurotherapeutics Ltd | Formulaciones de pridopidina de liberación modificada. |
-
2015
- 2015-01-21 MX MX2016009427A patent/MX377576B/es active IP Right Grant
- 2015-01-21 JP JP2016547847A patent/JP6949487B2/ja active Active
- 2015-01-21 WO PCT/US2015/012248 patent/WO2015112601A1/en not_active Ceased
- 2015-01-21 EA EA201691454A patent/EA201691454A1/ru unknown
- 2015-01-21 PE PE2016001263A patent/PE20161220A1/es not_active Application Discontinuation
- 2015-01-21 EP EP22163271.4A patent/EP4049657A1/en not_active Withdrawn
- 2015-01-21 UA UAA201608936A patent/UA122053C2/uk unknown
- 2015-01-21 EP EP15740303.1A patent/EP3096759B1/en active Active
- 2015-01-21 DK DK15740303.1T patent/DK3096759T3/da active
- 2015-01-21 AU AU2015209411A patent/AU2015209411A1/en not_active Abandoned
- 2015-01-21 US US14/601,920 patent/US20150202302A1/en not_active Abandoned
- 2015-01-21 PL PL15740303T patent/PL3096759T3/pl unknown
- 2015-01-21 CN CN201580005659.9A patent/CN106170287A/zh active Pending
- 2015-01-21 KR KR1020167022884A patent/KR102479759B1/ko active Active
- 2015-01-21 CA CA2937243A patent/CA2937243C/en active Active
- 2015-01-21 HU HUE15740303A patent/HUE058288T2/hu unknown
- 2015-01-21 ES ES15740303T patent/ES2911800T3/es active Active
- 2015-01-22 TW TW104102153A patent/TW201605446A/zh unknown
- 2015-01-22 UY UY0001035962A patent/UY35962A/es not_active Application Discontinuation
-
2016
- 2016-07-04 IL IL246598A patent/IL246598B/en active IP Right Grant
- 2016-07-22 CL CL2016001874A patent/CL2016001874A1/es unknown
-
2018
- 2018-08-28 US US16/115,105 patent/US20190209542A1/en not_active Abandoned
-
2019
- 2019-09-30 JP JP2019179329A patent/JP7266298B2/ja active Active
-
2021
- 2021-01-28 IL IL280485A patent/IL280485B2/en unknown
-
2023
- 2023-10-23 US US18/491,871 patent/US20240041855A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017503823A5 (https=) | ||
| JP6949487B2 (ja) | プリドピジンの調節放出製剤 | |
| JP6550157B2 (ja) | Ｇａｂａ類似体及びオピオイドを含む新規胃内滞留型剤形 | |
| JP2020023518A5 (https=) | ||
| JP2005526043A5 (https=) | ||
| JP2016516698A5 (https=) | ||
| US10874617B2 (en) | Oral pharmaceutical compositions of mesalazine | |
| JP2004534031A (ja) | 心臓および循環器疾患の治療および予防を目的とする一日一回の治療のための経口制御放出医薬組成物 | |
| AU2002314515A1 (en) | Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases | |
| US20140220127A1 (en) | Reduction of opioid blood fluctuations | |
| RU2015107517A (ru) | Фармацевтические композиции мемантина | |
| US11622938B2 (en) | Oral pharmaceutical compositions of nicotinamide | |
| US20140127294A1 (en) | Oral solid formulation of compound anti-tubercular drug and preparation method thereof | |
| KR20140045925A (ko) | 선택적 세로토닌 재흡수 억제제의 방출조절형 약제학적 조성물 | |
| JP2013536832A (ja) | ミルナシプランの制御放出医薬組成物 | |
| JP2014101332A (ja) | 徐放性塩酸アンブロキソール口腔内崩壊錠 | |
| CN102600095B (zh) | 一种氨溴索缓释制剂及其制备方法 | |
| AU2016382661B2 (en) | Process for preparation of an enteric coated granulate comprising dimethyl fumarate | |
| AU2004319799A1 (en) | Novel extended release composition of Venlafaxine hydrochloride containing polyvinyl acetate | |
| MX2010014153A (es) | Comprimido farmaceutico de liberacion controlada para administracion oral. | |
| KR20130106023A (ko) | 에페리손 함유 필름코팅정제, 및 이의 제조방법 | |
| KR20120103521A (ko) | 에페리손 함유 필름코팅정제, 및 이의 제조방법 | |
| CN104997749A (zh) | 控制释放制剂及其制备方法与用途 | |
| HK40005191A (en) | Oral pharmaceutical compositions of nicotinamide | |
| HK40005191B (en) | Oral pharmaceutical compositions of nicotinamide |